1 / 101

CASE PRESENTATION

CASE PRESENTATION. Puneet Khanna Moderator Dr. Anjolie Chhabra. www.anaesthesia.co.in anaesthesia.co.in@gmail.com. HISTORY. RAJESHWAR SINGH , 58 yrs , M R/O Bihar PRESENTING COMPLAINTS Loss of appetite for 6 months Weight loss for 4 months itching for 1 month

flynn
Download Presentation

CASE PRESENTATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CASE PRESENTATION Puneet Khanna Moderator Dr. Anjolie Chhabra www.anaesthesia.co.inanaesthesia.co.in@gmail.com

  2. HISTORY • RAJESHWAR SINGH , 58 yrs , M • R/O Bihar • PRESENTING COMPLAINTS • Loss of appetite for 6 months • Weight loss for 4 months • itching for 1 month • Yellow discoloration of eyes and skin for 15 days

  3. HISTORY OF PRESENT ILLNESS Anorexia (6months) • Loss of appetite was progressive • More than 50% Weight loss • Significant (10 Kg in 4 months)

  4. Itching (2-3 weeks) • all over body Jaundice (3 weeks) • Sudden onset (initially yellow sclera) • Progressive • continuous

  5. h/o low grade fever for 8 – 10 days • h/o single episode of fever with chills • h/o passage of high coloured dark yellow urine • h/o passage of clay coloured stool

  6. No h/o GI bleed or bleeding from any other site • No h/o abdominal pain • No h/o intake of medications • No h/o alcohol intake • No h/o contact with jaundiced individual • No h/o travel to hepatitis endemic area • No h/o blood or blood product transfusion

  7. PAST HISTORY • H/o D.M. recently diagnosed on OHA • NO H/o any other systemic illness • No h/o previous anaesthetic exposure or surgery

  8. PERSONAL HISTORY Chronic tobacco chewer • No h/o alcohol intake or drug abuse • Non vegetetarian • No alteration in bowel habbits

  9. FAMILY HISTORY Non contributary No family h/o jaundice

  10. GENERAL PHYSICAL EXAMINATION • Weight – 60 kg, Height – 175 cm • BMI - 19.59 • Moderate built and nourished • Yellow discolouration of sclera and all over the body (skin, nail) . Icterus • Pallor • NO edema ,clubbing ,Cyanosis, palpable lymphadenopathy

  11. VITALS • Afebrile • Pulse Rate – 80 per minute, regular, normal volume, all peripheral pulses palbable, no delay • Blood pressure – 120/70 mm of Hg right arm supine • Respiratory rate – 20 per minute, regular

  12. SYSTEMIC EXAMINATION ABDOMINAL EXAMINATION Inspection • Yellow discolouration of skin • No abdominal distension,dilated veins, pulsations Palpation • Soft, no tenderness • Hepatomegaly 4cm below costal margin, firm • No slenomegaly • No free fluid

  13. OTHER SYSTEMS Cardiovascular system S1 and S2 heard, no murmur. Chest Normal bronchovesicular breath sounds No added sounds Nervous system Normal

  14. AIRWAY EXAMINATION • Modified malampatti grade I • Mouth opening and neck movements adequate

  15. Provisional diagnosis

  16. INVESTIGATIONS Haemoglobin - 10 gm/dl Total leucocyte count – 13100 X10 3 / mm3 Differential count – P70 L18 E1 M5 Urea –14 mg% Creatinine – 1.1 mg% Na+ - 138 mEq/L , K+ - 3.8 mEq/L

  17. Bilrubin – 4.7mg (conj – 4.4, unconj – 0.3) Total protein – 8.0gm (albumin 2.3) SGOT- 61 IU, SGPT – 29 IU Alkaline phosphatase – 903 IU Prothrombin time -12/22 sec. PT after Vit K. – 12/15 sec. ECG and Chest X ray where normal.

  18. Final diagnosis • Obstructive jaundice probably malignant in origin, Childs-pughs B with no features suggestive of portal hypertension or liver failure

  19. ULTRASONOGRAPHY ABDOMEN • LIVER-14 cms cranio- caudal ,moderate intrahepatic duct dilatation • GB- distended , moderate amount of sludge seenwith small calculi • CBD-12cms dilated blocked at lower end by heterogenous mass • PANCREAS-periampullary pancreas atrophied ? Distal CBD mass ? Ampullary mass

  20. CECT - ABDOMEN • Moderate intrahepatic biliary dilation • CBD dilated till lower end (16 mm) • Small ill-defined soft tissue mass in ampulla of Vater (10 X 12 mm) • Gall bladder distended, no calculus. • No focal lesion in liver • Pancreatic parenchyma atrophic

  21. SIDE VIEWING ENDOSCOPY • Ampulla bulky • Moderate size growth • Polypoidal ,friable , ulcerated mass lesion with oozing blood in ampullary region ? Periampullary mass

  22. Anesthetic problems in Obstructive Jaundice ?

  23. PROBLEMS DUE TO DYSFUNCTION OF LIVER ITSELF : - Low serum proteins - Coagulopathy - Drug metabolism and disposition - Metabolic derangement - Hypoglycemia - Electrolyte imbalance - Haematological - Anaemia – Thrombocytopenia – Leucopenia – DIC - Deficiency of fat soluble vitamins (A, D, E, K) - Increased serum cholesterol (atheromatous changes)

  24. PROBLEMS DUE TO INVOLVEMENT OF OTHERSYSTEMS • CVS– TBV , PVR , Circulatory collapse • Renal - pre renal azotemia - Hepatorenal failure • GIT - Hm gastritis & stress ulcers • Resp.– Arterial Hypoxemia - vulnerability to pulmonary infection • CNS – Hepatic encephalopathy

  25. Problems related to surgery • Whipple’s procedure---Carc. Head of panc • Distal gastrectomy,PJ, HJ, GJ • Major surgery---long duration • Increased blood loss/fluid shifts • Wide incision---Roof top—warrants good postoperative analgesia • Extensive monitoring reqd for favourable outcome

  26. Age > 60 years Diabetes Hematocrit < 30% ESR > 50 Bilirubin >11mg% SGOT > 100 SGPT >100 Malignant disease Risk Factors for Postoperative Mortality Gut 1983; 24, 845-852

  27. Preoperative Assessment OBJECTIVES • Assess the type and degree of liver dysfunction. • Assess effect on other system. • To ensure – post operative facilities (High risk patient).

  28. Preoperative Assessment • History • Clinical examination • Investigations ??? Unexplained jaundice of 4wks duration or longer will prove to be caused by obstruction in nearly 75% patients Blumgart L

  29. Preoperative Investigations To know the pattern of disease : ­ S. Bilirubin ­ SGOT, SGPT 90% predictive ­ alk. phosphatase

  30. Preoperative Investigations To know the pattern of disease : ­ S. Bilirubin ­ SGOT, SGPT 90% predictive ­ alk. phosphatase

  31. Preoperative Investigations To judge the synthetic ability of liver • Serum albumin– < 2·5 gm% - severe damage • Albumin/globulin ratio – reversed. • Prothrombin time –> 1·5 sec. Over control – INR - > 1.3 (D/D – Par entral Vit. K – Obst. Jaundice)

  32. (i) Haematological · Hb TLC, DLC Platelet Count Clotting factors (PT, PTTK) BT (ii)Cardiorespiratory Chest X-ray ECG Blood gases (iii) Metabolic- Serum proteins Serum glucose Electrolyte Urea / Creatinine Urinary-Urea/ Creatinine -Electrolyte (iv) Hepatic imaging (v) Microbiological – - Culture -Hep. B marker - Viral antibodies To assess general condition of patient

  33. Preoperative management • Avoid prolonged hyperbilirubinemia • Treat infection –cholangitis • Use Aminoglycosides carefully • Avoid pre renal failure • Correct Anaemia/Coagulation/hypoalbuminemia • Avoid all NSAIDS • I/V saline & mannitol pre & postop

  34. Methods of Preoperative Drainage of Bile • Percutaneous catheter • Endoprosthesis • Endoscopic papillotomy

  35. Preoperative management No conclusive evidence for – • Preop percutaneous biliary drainage • Gut sterlization • Polymyxin B • Oral bile salts

  36. Premedication • Anxiolytic – oral short acting BDZ • Oral H2 antagonist • Vit. K (Obst. J) – 10 mg O D X 3 day • If Bilirubin > 8 mg% – · I/V fluid – 1-2 ml/kg/hr. · Mannitol / Furosemide/Dopamine • Order morning PT / S. Electrolyte • Preop urinary catheter & CVP

  37. Careful attention to perioperative hydration is the cornerstone in preserving adequate renal function. Other drugs do not confer additional protection. Hepatogastroenterology 2000;47:1691-1694

  38. Anaesthetic Management General Considerations Minimize physiological insult to liver & kidney • Maintain O2 supply – demand relationship in liver. →Adequate pulmonary ventilation and cardiovascular fn. • Maintain renal perfusion →Avoid Hypotension, hypoproteinemia & Hypoxia → meticulous fluid balance Choose appropriate anaesthetic agent

  39. Anesthetic technique • General anesthesia • Preoxygenation • Induction - Thiopentone, Etomidate – causes decrease in total hepatic blood flow ( due to dec CO) . • Propofol- increases total hepatic blood flow due to splanchnic vasodilation. Slow and titrated dose to avoid sudden hypotension • Ketamine- maintain hepatic blood flow • Avoid sympathetic stimulation during intubation as it will compromise hepatic blood flow

  40. CHOICE OF DRUGS FOR MAINTENANCE OF ANESTHESIA MUSCLE RELAXATION • Succinylcholine (RSI) • Atracurium or cis atracurium (drug of choice) • Vecuronium and Pancuronium– increase in elimination half life • Vecuronium and pancuronium do not alter hepatic blood flow

  41. Analgesia OPIOIDS • Protein bound • Metabolized by liver (except remifentanil) Morphine, pentazocine, meperidine, sufentanil, alfentanil  prolonged elimination half life  increased duration of action and can lead to respiratory depression

  42. Anesthetic technique • Opioids – Well tolerated Morphine—ph-II reac. fentanyl(DOC) spasm of sphincter of Oddi

  43. Anesthetic technique Spasm of sphincter of Oddi • Interpretation of operative cholangiography & biliary pressures • All patients do not show this response • Incidence of spasm is very low • Intraop manipulation of BD system  spasm • Treatment –Nalaxone, NTG, Glucagon, Atropine (partial)

  44. Fentanyl metabolism is not appreciably affected in patients with liver dysfunction BJA 1982;54:1267-1270 Remifentanil elimination unaltered by severe liver disease Morphine and fentanyl causes splanchnic vasodilation improving hepatic oxygen delivery Anesthesia and analgesia 1985; 64(6):577-584

  45. Anesthetic technique Volatile Anesthetics • Useful & well tolerated • Disadv- CVS instability  vasodilation perf. Press.  blood velocity  oxygen extraction  HBF & oxygen supply • Isoflurane—best maint. of HBF & oxygen

  46. Inhalational agents and hepatic blood flow

  47. Anesthetic technique IPPV – - Maintain eucapnia - Liver low pr.tissue bed - Avoid large VT & high airway pressures

  48. Anesthetic technique • Maintenance of BV and Renal function • Mannitol • Frusemide • Dopamine • Adequate blood/component replacement

  49. REGIONAL ANESTHESIA AS SUPPLEMENT TO G.A. • EPIDURAL ANESTHESIA • SUBARACHNOID MORPHINE • COELIAC PLEXUS BLOCK • CONCERNS– Coagulopathy, Hypotension • Duaration of action of xylocaine

  50. Intra Operative Monitoring • ECG, Pulse Oximetery, NIBP • EtCO2 • Urine output • Core temp • NMJ monitoring • Blood loss Biochemical B.Sugar,ABG S.Electrolytes Hematological Hb,PT,,PTTK,TEG Long and extensive Cvp, Intra arterial

More Related